Specialty Care
Clinical positioning
Dermatological ghrita for clinician-led skin rasayana and inflammatory skin-support discussions.
Clinical use lens
Skin ECS logicFor dermatology support conversations where skin ECS, inflammatory tone and barrier comfort are relevant.
Protocol mapping
Indication fit
Inflammatory skin support
Reactive skin
Skin barrier
Topical/internal contexts
Why doctors reach for it
Clinical highlights
✦Skin support: dermatological ghrita for inflammatory/reactive skin contexts
✓Barrier logic: ghrita base supports lipid delivery and skin comfort rationale
→Classical actives: Daruharidra, Lodhra and Triphala group support skin rasayana logic
How it is positioned to work
Mechanism map
1Skin endocannabinoid-system and inflammatory signalling support
2Ghrita base supports lipid delivery and skin barrier rationale
3Daruharidra, Lodhra and Triphala group support classical skin rasayana positioning
Route boundary
Administration & dosing
◌
External skin application
CannoDerma is a local skin application, not an edible body-weight-dosed product.No X-based mg calculation
ApplicationApply locally as directed for the intended skin area.
ReviewDocument application area, frequency and local tolerance.
⏱
Timing and documentation
Use according to the product direction and treating clinician plan.
✓
Administration boundary
External use only. It is excluded from X-based cannabinoid mg calculations.
Rx
Doctor instruction
Record the product, route, amount, timing, application or rinse method, duration and follow-up response.
In-clinic use
Correct administration & safety boundary
Correct administration
- Application: Apply locally as directed for the intended skin area.
- Review: Document application area, frequency and local tolerance.
- Classification: external / non-edible.
The X-based systemic dose framework is intentionally removed for this product.
Safety boundary
- For registered medical practitioners only
- Select dose by clinical context and tolerability
- Monitor sedation, interactions and follow-up response
- Not for direct patient promotion
9 actives
Formula / ingredients
| Ingredient | Botanical / base | Part | Qty |
|---|---|---|---|
| Cannabis/Hemp/Vijaya Leaf or plant (Sativa Plant) | Cannabis Sativa linn | Leaf | 5gms (5%) |
| Daruharidra | Berberis aristata | Root | 5gms (5%) |
| Lodhra | Symplocos racemosa Roxb | Bark | 5gms (5%) |
| Musta | Cyperus rotundus L. | Rhizome | 5gms (5%) |
| Amalaki | Emblica officinalis Gaertn. | Fruit | 5gms (5%) |
| Haritaki | Terminalia chebula | Fruit | 5gms (5%) |
| Vibhitaki | Terminalia bellerica | Fruit | 5gms (5%) |
| Sariva | Hemidesmus indicus | Root | 5gms (5%) |
| Goghrita | Cow’s Ghee | - | 60 ml (60%) |
Clinic packs
Pack / MRP
| Pack | Strength | MRP |
|---|---|---|
| Dermatological ghrita pack | Clinical pack | Price on request |
Pack / MRP summary: Dermatological ghrita pack Price on request
3 source links
Audited research links
| Audited reference fit | Clinical logic | Source |
|---|---|---|
| Skin ECS ✓ Specialty logic checkedPubMed / PMIDScientific context The endocannabinoid system of the skin | Endocannabinoid system in skin health/disease | Open ↗ |
| Cannabinoids / skin ✓ Specialty logic checkedPubMed / PMIDMechanistic rationale Potential role of cannabinoids in dermatology | Dermatology review of cannabinoid mechanisms | Open ↗ |
| Cannabinoids / skin inflammation ✓ Pain/inflammation checkedPubMed / PMIDScientific context Cannabinoids for autoimmune and inflammatory skin disease | Autoimmune and inflammatory skin disease review | Open ↗ |
Educational use only. Doctor-facing scientific aid only. Research links are mapped for ingredient rationale, mechanism, clinical context and safety boundaries. This brochure does not replace diagnosis, standard-of-care treatment, regulatory prescribing rules or clinical monitoring. See our legal & medical disclaimer and editorial policy.
Same protocol
